Publication: GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap
| dc.contributor.author | Roman-Rodriguez, Miguel | |
| dc.contributor.author | Kaplan, Alan | |
| dc.date.accessioned | 2024-09-18T06:42:08Z | |
| dc.date.available | 2024-09-18T06:42:08Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may [...] coexist in an individual patient. If a concurrent diagnosis of asthma is suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non-pharmacological approaches may also be needed for their COPD. What does this mean for the treating physician? In this review, we explore the implications of this new guidance on treating patients with chronic obstructive pulmonary disease, arguing for a personalized approach to treatment. | en |
| dc.description.sponsorship | Medical writing assistance was provided by Olive Denneny, MSc, of MediTech Media (UK) and was funded by Boehringer Ingelheim. | es_ES |
| dc.format.page | 1709-1715 | es_ES |
| dc.format.volume | 16 | es_ES |
| dc.identifier.citation | Roman-Rodriguez M, Kaplan A. GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap. Int J Chronic Obstr Pulm Dis. 2021;16:1709-15. | en |
| dc.identifier.doi | 10.2147/COPD.S300902 | |
| dc.identifier.issn | 1178-2005 | |
| dc.identifier.journal | International Journal of Chronic Obstructive Pulmonary Disease | es_ES |
| dc.identifier.other | https://hdl.handle.net/20.500.13003/19610 | |
| dc.identifier.pubmedID | 34163155 | es_ES |
| dc.identifier.pui | L2007625886 | |
| dc.identifier.scopus | 2-s2.0-85108723989 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/23169 | |
| dc.identifier.wos | 662308400001 | |
| dc.language.iso | eng | en |
| dc.publisher | Dove Medical Press | |
| dc.relation.publisherversion | https://dx.doi.org/10.2147/COPD.S300902 | en |
| dc.rights.accessRights | open access | en |
| dc.rights.license | Attribution 4.0 International | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | COPD | |
| dc.subject | Asthma | |
| dc.subject | Asthma-COPD overlap | |
| dc.subject | Inhaled corticosteroid | |
| dc.subject | Bronchodilator | |
| dc.subject.decs | Enfermedad Pulmonar Obstructiva Crónica | * |
| dc.subject.decs | Humanos | * |
| dc.subject.decs | Asma | * |
| dc.subject.mesh | Asthma | * |
| dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | * |
| dc.subject.mesh | Humans | * |
| dc.title | GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap | en |
| dc.type | research article | en |
| dspace.entity.type | Publication | |
| relation.isPublisherOfPublication | ba22643b-836b-4738-8dc3-444eb4bd4ec4 | |
| relation.isPublisherOfPublication.latestForDiscovery | ba22643b-836b-4738-8dc3-444eb4bd4ec4 |


